{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:52:11Z","timestamp":1758127931330},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T00:00:00Z","timestamp":1528848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T00:00:00Z","timestamp":1528848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Delta-Fly Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s10637-018-0615-8","type":"journal-article","created":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T01:54:52Z","timestamp":1528854892000},"page":"895-902","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer"],"prefix":"10.1007","volume":"36","author":[{"given":"Amir","family":"Mehrvarz Sarshekeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry Q.","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzo","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard S.","family":"Hochster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Kopetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,13]]},"reference":[{"issue":"1","key":"615_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7\u201330","journal-title":"CA Cancer J Clin"},{"key":"615_CR2","unstructured":"National Comprehensive Cancer Network. Colon Cancer (Version 2.2018). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf. Accessed 1 June 2018"},{"issue":"26","key":"615_CR3","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1021\/jm00078a006","volume":"36","author":"A Azuma","year":"1993","unstructured":"Azuma A, Nakajima Y, Nishizono N, Minakawa N, Suzuki M, Hanaoka K et al (1993) Nucleosides and nucleotides. 122. 2'-C-cyano-2\u2032-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum. J Med Chem 36(26):4183\u20134189","journal-title":"J Med Chem"},{"issue":"17","key":"615_CR4","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1021\/jm00017a023","volume":"38","author":"A Azuma","year":"1995","unstructured":"Azuma A, Hanaoka K, Kurihara A, Kobayashi T, Miyauchi S, Kamo N et al (1995) Nucleosides and nucleotides. 141. Chemical stability of a new antitumor nucleoside, 2'-C-cyano-2\u2032-deoxy-1-beta-D-arabino-pentofuranosylcytosine in alkaline medium: formation of 2'-C-cyano-2\u2032-deoxy-1-beta-D-ribo-pentofuranosylcytosine and its antitumor activity. J Med Chem 38(17):3391\u20133397","journal-title":"J Med Chem"},{"issue":"2","key":"615_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1349-7006.2004.tb03189.x","volume":"95","author":"A Matsuda","year":"2004","unstructured":"Matsuda A, Sasaki T (2004) Antitumor activity of sugar-modified cytosine nucleosides. Cancer Sci 95(2):105\u2013111","journal-title":"Cancer Sci"},{"issue":"2","key":"615_CR6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/(SICI)1097-0215(19990719)82:2<226::AID-IJC13>3.0.CO;2-X","volume":"82","author":"K Hanaoka","year":"1999","unstructured":"Hanaoka K, Suzuki M, Kobayashi T, Tanzawa F, Tanaka K, Shibayama T et al (1999) Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682). Int J Cancer 82(2):226\u2013236","journal-title":"Int J Cancer"},{"issue":"4","key":"615_CR7","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1124\/mol.59.4.725","volume":"59","author":"A Azuma","year":"2001","unstructured":"Azuma A, Huang P, Matsuda A, Plunkett W (2001) 2'-C-cyano-2\u2032-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest. Mol Pharmacol 59(4):725\u2013731","journal-title":"Mol Pharmacol"},{"issue":"5 Suppl 10","key":"615_CR8","first-page":"3","volume":"23","author":"W Plunkett","year":"1996","unstructured":"Plunkett W, Huang P, Searcy CE, Gandhi V (1996) Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 23(5 Suppl 10):3\u201315","journal-title":"Semin Oncol"},{"issue":"3","key":"615_CR9","first-page":"851","volume":"52","author":"K Iizuka","year":"2018","unstructured":"Iizuka K, Zhang C, Eshima K, Jin C, Eshima K, Fukushima M (2018) Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo. Int J Oncol 52(3):851\u2013860","journal-title":"Int J Oncol"},{"key":"615_CR10","doi-asserted-by":"crossref","unstructured":"Sankhala KK, Takimoto CH, Mita AC, Xiong H, Rodon J, Adinin R, Burns K, Toko T, Arakawa K, Kopetz S. (2008) Two phase I, pharmacokinetic (PK) and pharmacodynamic (PD) studies of TAS-109, a novel nucleoside analogue with 14 days and 7 days continuous infusion (CI) schedules. J Clin Oncol 26, no. 15_suppl 2577\u20132577","DOI":"10.1200\/jco.2008.26.15_suppl.2577"},{"issue":"3","key":"615_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"615_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31\u201341","journal-title":"Nephron"},{"issue":"1","key":"615_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1\u201310","journal-title":"Control Clin Trials"},{"key":"615_CR14","unstructured":"Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003 (http:\/\/ctep.cancer.gov), Publish Date: August 9, 2006"},{"issue":"9 Supplement","key":"615_CR15","first-page":"116","volume":"68","author":"S Shord","year":"2008","unstructured":"Shord S, Patel S (2008) Gene expression ratio of deoxycytidine kinase (dCK) to cytidine deaminase (CDA) corresponds with cytotoxicity in solid tumors in vitro. Cancer Res 68(9 Supplement):116","journal-title":"Cancer Res"},{"issue":"1","key":"615_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/mutage\/18.1.45","volume":"18","author":"A Hartmann","year":"2003","unstructured":"Hartmann A, Agurell E, Beevers C, Brendler-Schwaab S, Burlinson B, Clay P et al (2003) Recommendations for conducting the in vivo alkaline Comet assay. 4th International Comet Assay Workshop. Mutagenesis 18(1):45\u201351","journal-title":"Mutagenesis"},{"issue":"1","key":"615_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2307\/3577587","volume":"122","author":"PL Olive","year":"1990","unstructured":"Olive PL, Banath JP, Durand RE (1990) Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the \"comet\" assay. Radiat Res 122(1):86\u201394","journal-title":"Radiat Res"},{"key":"615_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2307\/2530286","volume":"38","author":"R Brookmeyer","year":"1982","unstructured":"Brookmeyer R, Crowley JJ (1982) A confidence interval for the median survival time. Biometrics 38:29\u201341","journal-title":"Biometrics"},{"issue":"20","key":"615_CR19","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372(20):1909\u20131919","journal-title":"N Engl J Med"},{"issue":"9863","key":"615_CR20","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303\u2013312","journal-title":"Lancet"},{"key":"615_CR21","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, Jabbour EJ, Garcia-Manero G, Kadia TM, DiNardo CD, Daver NG, et al. (2016) Phase I\/II study of DFP-10917 in relapsed\/refractory AML demonstrates efficacy and safety profile suitable for phase III study. Blood 128-2822 Abstract","DOI":"10.1182\/blood.V128.22.2822.2822"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0615-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0615-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0615-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:25:08Z","timestamp":1678559108000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0615-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,13]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["615"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0615-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,13]]},"assertion":[{"value":"11 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All authors declare no potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent to participate in the study was obtained from each patient before study enrollment and the performance of any study-specific procedures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}